Vigil Neuroscience (NASDAQ:VIGL) Price Target Cut to $17.00 by Analysts at HC Wainwright

Vigil Neuroscience (NASDAQ:VIGL) had its target price trimmed by HC Wainwright from $24.00 to $17.00 in a report issued on Friday morning, Benzinga reports. The firm currently has a buy rating on the stock.

Other equities research analysts have also recently issued reports about the company. Wedbush reaffirmed an outperform rating and set a $23.00 price target on shares of Vigil Neuroscience in a report on Thursday, July 11th. JMP Securities restated a market outperform rating and issued a $23.00 target price on shares of Vigil Neuroscience in a research note on Thursday, April 18th.

Vigil Neuroscience Stock Performance

Shares of NASDAQ VIGL opened at $3.72 on Friday. The business has a fifty day moving average of $3.87 and a two-hundred day moving average of $3.36. Vigil Neuroscience has a 52-week low of $2.47 and a 52-week high of $9.24. The stock has a market cap of $139.81 million, a PE ratio of -1.75 and a beta of 2.00.

Vigil Neuroscience (NASDAQ:VIGL) last announced its quarterly earnings results on Tuesday, May 7th. The company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.60) by $0.10. Analysts predict that Vigil Neuroscience will post -2.1 earnings per share for the current year.

Institutional Trading of Vigil Neuroscience

A hedge fund recently bought a new stake in Vigil Neuroscience stock. Strs Ohio acquired a new position in shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 8,200 shares of the company’s stock, valued at approximately $27,000. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.